Abstract
Objective:To evaluate the anti-cancer properties of Caesalpinia sappan and Ficus septica in combination with doxorubicin on 4T1 cells, confirm their nephroprotective activities, and predict the molecular targets of the underlying mechanisms. Methods:The cytotoxic activities of all extracts and doxorubicin were determined by MTT assay followed by cell cycle and apoptosis analysis using flow cytometry. Immunoblotting was used to determine the protein expressions. The proteins involved in the cell proliferation and migration were analyzed through bioinformatics approaches, whereas, the interaction between compounds and protein targets was observed through molecular docking. Furthermore, the effect of the extracts on cell migration was analyzed by scratch wound healing assay. The intracellular ROS after treatment with extracts was observed using DCFDA staining flow cytometry.Results:Both ECS and EFS performed cytotoxic properties and significantly enhanced doxorubicin’s cytotoxic effects against 4T1 cells. However, these cytotoxic activities did not correlate with the cell cycle progression. On the contrary, the combination treatment caused apoptosis that may correlate with the decreasing of IκBα phosphorylation, indicating that all agents targeted the inhibition of NF-κB activation. The combination treatments also inhibited cell migration and decreased MMP-9 expression. TNBC proliferation and metastasis needed at least 54 proteins to be activated, some of them are related to NF-κB activation. The inhibitory effect of ECS correlated with the interaction of brazilin and brazilein to IKK, a kinase protein that plays a role in IκBα phosphorylation. In addition, ECS and EFS reduced ROS expression in Vero cells caused by doxorubicin. Conclusion:In conclusion, ECS and EFS effectively enhanced the cytotoxic effect of doxorubicin and inhibit cell migration on 4T1 cells and these activities may correlate to the inhibitory effect of NF-κB activation. ECS and EFS also exhibit ROS suppressing effect on Vero cells that may be beneficent to reduce nephrotoxicity of chemotherapeutic treatment.
Highlights
The triple negative breast cancer (TNBC) subtype of breast cancer is a kind of aggressive breast cancer with limited treatment choices (Yin et al, 2020)
In conclusion, extracts of sappan wood (ECS) and EFS effectively enhanced the cytotoxic effect of doxorubicin and inhibit cell migration on 4T1 cells and these activities may correlate to the inhibitory effect of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation
We performed an MTT assay to evaluate the cytotoxicity of ECS, EFS, and doxorubicin employing 4T1, a TNBC and elicit metastatic characteristics
Summary
The triple negative breast cancer (TNBC) subtype of breast cancer is a kind of aggressive breast cancer with limited treatment choices (Yin et al, 2020). This strain exhibits relatively higher resistance to standard chemotherapy, anthracyclines and taxanes, especially in the metastatic stage (Wahba and El-Hadaad, 2015). Existing chemotherapeutic agents have a number of drawbacks, including resistance, side effects, and insufficient efficacy in advanced cancers. In metastatic breast cancer types, doxorubicin induces lamellipodia formation which plays an important role in cell migration (Meiyanto et al, 2019). Figuring out the best regiment and use of cochemotherapeutic agents to suppress or even alleviate the side effects of chemotherapy is an interesting challenge
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Asian Pacific journal of cancer prevention : APJCP
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.